Agendia's NGS-Based MammaPrint® BluePrint® Kit Wins Best Technological Innovation -- Diagnostics at the Medtech Insight Awards
A panel of independent experts commended the clinical utility of the 'practice-changing' breast cancer recurrence and molecular subtyping kit, which can be run in-house, giving more patients access to the benefits of precision oncology
IRVINE, Calif. and AMSTERDAM, Sept. 25, 2018 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology, announced that its MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit was named Best Technological Innovation – Diagnostics at the inaugural Medtech Insight Awards in Philadelphia on Sunday.
The award, which was based on significant contributions to advancing patient treatment through diagnostics, recognized the value of the next-generation sequencing (NGS)-based MammaPrint BluePrint Kit for broadening access to tests that personalize breast cancer management, in addition to the drive and teamwork involved in the rapid delivery of the test to the market.
The Medtech Insight judging panel said:
"Agendia's new decentralized kit allows cancer centers to run practice-guiding genomic tests in-house, broadening access for breast cancer patients to more informed personalized treatment. The system was developed in less than a year by the company in collaboration with industry partners and cancer centers. An excellent concept and great example of partnering and collaboration to achieve a breakthrough."
Annuska Glas, Ph.D., Vice President R&D and Product Support at Agendia, said:
"We believe that every breast cancer patient deserves access to best-in-class genomic testing to personalize breast cancer treatment management so they can live the longest, healthiest lives possible. We are pleased and very grateful that the Medtech Insight judging panel has recognized the value of our kit to help us deliver on this for as many women as possible. We dedicate this award to our R&D, operational, clinical and commercial teams who worked so hard to deliver on this important project, to our development partners Agilent and Bluebee, and to our colleagues at the prestigious co-validation centers, Institut Curie in France and UZ Leuven in Belgium."
The MammaPrint BluePrint Kit is an RNA-sequencing based version of Agendia's existing MammaPrint and BluePrint tests, which are currently performed centrally at the Company's CLIA-certified and CAP-accredited laboratories in Irvine, CA and Amsterdam, the Netherlands. The Kit enables leading cancer centers in Europe and beyond to run these tests in their own labs, using their existing NGS instruments, for the first time.
Agendia's MammaPrint test analyzes 70 genes most associated with breast cancer recurrence to provide a clear Low or High Risk of distant recurrence result, while BluePrint analyzes 80 genes, which classify a patient's breast cancer into functional molecular subtypes. The MammaPrint BluePrint Kit combines both MammaPrint and BluePrint to aid physicians in personalizing treatment management decisions for their patients by identifying women with early-stage breast cancer who are at a genomic Low or High Risk for distant metastasis within five years.
To learn more about the MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit, visit: www.agendia.com/diagnostic-products (Europe only)
About MammaPrint
MammaPrint is an in vitro diagnostic medical device, performed as a testing service in a central laboratory, using the 70-gene expression profile of breast cancer tissue samples to assess a patient's risk for distant metastasis. The device is FDA-cleared and CE-marked, enabling use in the European Union. MammaPrint is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. It is not intended to determine the outcome of disease, nor to suggest or infer an individual patient's response to therapy.
About BluePrint
BluePrint is an 80-gene complementary laboratory-developed test provided with MammaPrint which allows functional molecular subtyping of a breast cancer sample into three distinct subtypes: Luminal-type, HER2-type and Basal-type, each with marked differences in long-term outcome and response to neoadjuvant chemotherapy.
About Agendia
Agendia is a privately held, leading precision oncology company that develops and markets genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. The company's offerings include the MammaPrint Breast Cancer Risk-of-Recurrence Test, and the BluePrint Molecular Subtyping Test, both on microarray technology, whereas the new MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit, is on NGS technology.
The MammaPrint BluePrint next-generation sequencing-based kit is a CE-marked device currently available for use in cancer centers in select regions of the world.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology.
For more information on Agendia or the MammaPrint and BluePrint tests, visit www.agendia.com. Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news.
Media Contacts
Weber Shandwick
Heather Platisha
+1 (206) 576-5558
[email protected]
SOURCE Agendia, Inc.
Share this article